ALS, Denali
Denali slides after ALS drug flunks clinical test
The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly after one FDA-approved therapy – Amylyx's Relyvrio/Albrioza (sodium phenylbutyrate/taurursodiol) – was pulled from the market.
Stock futures were rising modestly Tuesday, a day after tech shares helped lift the S&P 500 to its second straight gain.These ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
New research on the Denali Fault reveals three geologic sites were once united in a suture zone, marking the integration of ...
President-elect Donald Trump has announced plans to change the name of Mount Denali in Alaska back to Mount McKinley, ...
Fort Smith area plaintiffs have not shown they suffered physical harm from an intermittent but widespread offensive smell in ...
Then-US President Barack Obama officially returned North America's tallest mountain to its Indigenous name in 2015 - Anadolu ...
Denali Bancorporation, Inc., the parent company of Denali State Bank, announced a $0.05 increase in its quarterly cash ...
Mashpee Wampanoag educator Kitty Hendricks-Miller (Nanaweetah), consults on PBS 'Molly of Denali' as Cape-based tribe debuts ...
Hosted on MSN3d
William Blair Initiates Coverage of Denali Therapeutics (DNLI) with Outperform RecommendationFintel reports that on January 3, 2025, William Blair initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback